The Dog Aging Project: Unraveling Canine and Human Longevity
The Dog Aging Project, a collaborative research initiative involving over 50,000 dogs, is investigating the biology of aging and cognitive decline in canines to inform both veterinary and human medicine. The project collects extensive data on dog health, lifestyle, and brain pathology, revealing similarities between canine and human dementia, and is conducting trials on potential longevity-enhancing drugs like rapamycin.
Project Overview and Methodology
The Dog Aging Project, co-founded in 2014 by biologist Matt Kaeberlein, aims to understand the aging process in dogs and apply this knowledge to promote healthier, longer lives for both canines and humans. The initiative is built on the premise that dogs develop many age-related diseases similar to humans, including dementia and cancer. Their brains share structural similarities with human brains, and they live in comparable environments, making them valuable models for studying disease progression and aging.
Veterinary neurologist Stephanie McGrath notes that dogs' faster aging process allows scientists to gather extensive information more quickly than in human studies, serving as an intermediate step between mouse and human trials.
Participating dogs contribute data through:
- Dietary information
- Exercise routines
- Blood samples
- Brain MRI scans
- Physical and mental fitness tests, including short-term memory tasks involving hidden treats.
Data from the project is compiled into a public database, which has been utilized in over 50 scientific studies.
Insights into Canine Cognitive Decline
Neuropathologist Dr. Dirk Keene from the University of Washington, who has studied human brains for two decades, collaborates with the project to examine donated dog brains. His research has revealed similarities in how dementia affects brain size and structure in both dogs and humans. Dementia in both species leads to brain shrinkage and enlargement of internal cavities due to neuron loss.
Specific findings include:
- Microscopic examination of a dog's brain, such as that of Dr. Keene's dog Spring, has shown beta amyloid plaques, which are recognized hallmarks of Alzheimer's disease in humans.
- MRI scans performed on dogs like Ralph, who was diagnosed with dementia in February 2025, showed increased white pockets, indicating fluid filling spaces left by brain shrinkage, compared to healthy dog brains.
- Behavioral changes observed in dogs with dementia, such as anxiety, confusion, disorientation, aimless wandering, and staring into space, mirror symptoms seen in human Alzheimer's. Ralph, for example, exhibited aimless wandering during memory tests.
Research from the project has also identified correlations between lifestyle and disease risk. Key findings include:
- Dogs living with other dogs exhibiting fewer diseases.
- Dogs that do not exercise having a six-fold higher chance of developing dementia.
Drug Research: Rapamycin Trials
The project is investigating potential treatments for age-related conditions, including the drug rapamycin, which has been shown in mice to slow cognitive decline and increase life expectancy by 60%.
Molecular biologist Julie Moreno led a pilot study involving 12 dogs exhibiting dementia symptoms to assess rapamycin's effects. Post-mortem analysis of brains from dogs in the study, including Ralph and a dog named Monkey who received rapamycin, showed fewer microglial cells. Microglial cells are associated with inflammation linked to dementia. Subsequent examinations of two other dogs treated with rapamycin also indicated reduced inflammation-related cells.
Based on these results, a larger clinical trial, partly funded by the National Institutes of Health, is currently underway. This trial involves hundreds of dogs, including a 12-year-old German shepherd-poodle mix named Murphy, receiving either a placebo or rapamycin to determine its impact on life extension and healthy aging.
Broader Longevity Efforts
In addition to the Dog Aging Project's trials, Loyal, a for-profit biotech startup founded by Celine Haliou in 2019, is developing and testing three other aging drugs for dogs. Loyal's objective is to create a daily preventative pill to extend dogs' healthy lifespans by approximately one year. One of Loyal's drugs, currently in a clinical trial for dogs over 10, has received FDA clearance for safety data and a "Reasonable Expectation of Effectiveness," with final trial results anticipated in several years. These efforts in canine longevity research are viewed as a potential pathway to advancing human longevity research.
Experts suggest that maintaining activity, mental engagement, and a balanced diet may contribute to protecting canine brain health, similar to recommendations for humans.